• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Profound Medical Corp.

    11/14/24 4:27:34 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care
    Get the next $PROF alert in real time by email
    SC 13G/A 1 profound_13ga7.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 7)*
     
    Profound Medical Corp.
    (Name of Issuer)
     
    Common Shares
    (Title of Class of Securities)
     
    74319B502
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)
       

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).  

     
     
    CUSIP No. 74319B502 13G Page 2 of 8

     

                 
    1.

    Names Of Reporting Persons

    Gagnon Securities LLC

     

     
           
    2. check the appropriate box if a group (a) o
    (b) x

    3. sec use only    
           
    4.

    citizenship or place of organization

     

    Delaware Limited Liability Company

     

       
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    5. sole voting power     0
    6. shared voting power     1,574,737
    7. sole dispositive power     0
    8. shared dispositive power     1,713,170
    9. aggregate amount beneficially owned by each reporting person   1,713,170
    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
    11. percent of class represented by amount in row (9)  

    7.0%

    12. type of reporting person (See Instructions)     IA, BD

     

     
     
     
    CUSIP No. 74319B502 13G Page 3 of 8

     

                 
    1.

    Names Of Reporting Persons

    Gagnon Advisors, LLC

     

     
           
    2. check the appropriate box if a group (a) o
    (b) x

    3. sec use only    
           
    4.

    citizenship or place of organization

     

    Delaware Limited Liability Company

     

       
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    5. sole voting power     0
    6. shared voting power     747,226
    7. sole dispositive power     0
    8. shared dispositive power    

    747,226

    9. aggregate amount beneficially owned by each reporting person  

    747,226

    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
    11. percent of class represented by amount in row (9)  

    3.0%

    12. type of reporting person (See Instructions)     IA

     

     
     
     
    CUSIP No. 74319B502 13G Page 4 of 8

     

                 
    1.

    Names Of Reporting Persons

    Neil Gagnon

     

     
           
    2. check the appropriate box if a group (a) o
    (b) x

    3. sec use only    
           
    4.

    citizenship or place of organization

     

    USA

     

       
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    5. sole voting power    

    262,662

    6. shared voting power    

    2,492,006

    7. sole dispositive power    

    262,662

    8. shared dispositive power    

    2,642,744

    9. aggregate amount beneficially owned by each reporting person  

    2,905,406

    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
    11. percent of class represented by amount in row (9)  

    11.8%

    12. type of reporting person (See Instructions)     IN

     

     
     
     
    CUSIP No. 74319B502 13G Page 5 of 8
    Item 1.  

     

    (a) Name of Issuer: Profound Medical Corp.
         
    (b) Address of Issuer’s Principal

    2400 Skymark Avenue, Unit 6

      Executive Offices:

    Mississauga, Ontario L4W 5K5

     

    Item 2.

    (a) Name of Person Filing:

    Neil Gagnon has sole voting and dispositive power over 262,662 shares of the Issuer’s Common Shares (the “Common Shares”). In addition, Mr. Gagnon has shared voting power over 2,492,006 Common Shares and shared dispositive power over 2,642,744 Common Shares.

     

    Mr. Gagnon is the managing member and principal owner of Gagnon Securities LLC (“GS”), an investment adviser registered with the U.S. Securities and Exchange Commission (“SEC”) under the Investment Advisers Act of 1940, as amended (the “Advisers Act”), and a registered broker-dealer, in its role as investment manager to several customer accounts, foundations, partnerships and trusts (collectively, the “Accounts”) to which it furnishes investment advice. GS and Mr. Gagnon may be deemed to share voting power with respect to 1,574,737 Common Shares held in the Accounts and dispositive power with respect to 1,713,170 Common Shares held in the Accounts. GS and Mr. Gagnon expressly disclaim beneficial ownership of all securities held in the Accounts.

     

    Mr. Gagnon is also the Chief Executive Officer of Gagnon Advisors, LLC (“Gagnon Advisors”), an investment adviser registered with the SEC under the Advisers Act. Mr. Gagnon and Gagnon Advisors, in its role as investment manager to Gagnon Investment Associates, LLC (“GIA”), a private investment fund, may be deemed to share voting and dispositive power with respect to the 747,226 Common Shares held by GIA. Gagnon Advisors and Mr. Gagnon expressly disclaim beneficial ownership of all securities held by GIA.

     

    (b) Address of Principal Business Office 1370 Ave. of the Americas, 26th Floor
      or, if none, Residence: New York, NY 10019

     

    (c) Citizenship:

    Gagnon Securities LLC

    Delaware limited liability company

       

    Gagnon Advisors, LLC

    Delaware limited liability company

       

    Neil Gagnon

    USA

         
    (d) Title of Class of Securities:

    Common Shares

         
    (e) CUSIP Number: 74319B502

     

     
     
     
    CUSIP No. 74319B502 13G Page 6 of 8
       
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)  o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b)  o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c)  o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d)  o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
         
    (e)  o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f)  o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g)  o A parent holding company or control person in accordance with § 13d-1(b)(1)(ii)(G);
         
    (h)  o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i)  o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15U.S.C. 80a-3);
         
    (j)  o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k)  o Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

     
     
     
    CUSIP No. 74319B502 13G Page 7 of 8
    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:

    Gagnon Securities LLC

    1,713,170

         

    Gagnon Advisors, LLC

    747,226

         

    Neil Gagnon

    2,905,406

           
      (b) Percent of class:

    Gagnon Securities LLC

    7.0%

         

    Gagnon Advisors, LLC

    3.0%

         

    Neil Gagnon

    11.8%

           
         

    Calculation of percentage of beneficial ownership is based on 24,661,771 Common Shares outstanding as of September 30, 2024, based on the Issuer’s Form 6-K filed with the Securities and Exchange Commission on November 7, 2024.

           
      (c) Number of shares as to which the person has:

     

      (i) Sole power to vote or to direct the vote:

    Gagnon Securities LLC

    0

         

    Gagnon Advisors, LLC

    0
         

    Neil Gagnon

    262,662

           
      (ii) Shared power to vote or to direct the vote:

    Gagnon Securities LLC

    1,574,737

         

    Gagnon Advisors, LLC

    747,226

         

    Neil Gagnon

    2,492,006

           
      (iii) Sole power to dispose or to direct the disposition of:

    Gagnon Securities LLC

    0
         

    Gagnon Advisors, LLC

    0
         

    Neil Gagnon

    262,662

           
      (iv) Shared power to dispose or to direct the disposition of:

    Gagnon Securities LLC

    1,713,170

         

    Gagnon Advisors, LLC

    747,226

         

    Neil Gagnon

    2,642,744

     

    Item 5. Ownership of Five Percent or Less of a Class.
       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    The Accounts described above in Item 2 have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, securities held in their respective accounts. To the knowledge of the Reporting Persons the interest in any such account does not exceed 5% of the class of securities. Except to the extent described herein, the Reporting Person disclaims beneficial ownership of all such securities.

     

    Items 7 – 9. Not Applicable.

     

     
     
     
    CUSIP No. 74319B502 13G Page 8 of 8
       
    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 230.14a-11.

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     
      NEIL GAGNON
       

    /s/ Neil Gagnon

       
     

    GAGNON SECURITIES LLC

       
     

    /s/ Neil Gagnon

      Name:  Neil Gagnon
     

    Title:    Managing Member

       
     

    GAGNON ADVISORS, LLC

       
     

    /s/ Neil Gagnon

      Name:  Neil Gagnon 
     

    Title:    Chief Executive Officer

       
     
     
    Get the next $PROF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PROF

    DatePrice TargetRatingAnalyst
    7/23/2024$16.50Buy
    Lake Street
    7/16/2024$9.00 → $12.00Hold → Buy
    Stifel
    11/28/2023$11.00Hold
    Stifel
    8/4/2023$20.00 → $200.00Strong Buy → Outperform
    Raymond James
    3/21/2023$5.50 → $10.00Buy → Hold
    Jefferies
    3/7/2022$28.00 → $14.00Outperform
    Cowen & Co.
    2/22/2022$28.00 → $23.00Strong Buy → Outperform
    Raymond James
    More analyst ratings

    $PROF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Famed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO®

      TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce that it has entered into a consulting agreement with Leonard Wheeler, a former NFL player turned entrepreneur, author, corporate consultant, co-Executive Director of the NFL Legends Community, and more recently, national podcaster. This landmark partnership ushers in a dynamic new chapter for Profound, whereby Mr. Wheeler, who successfully underwent the TULSA procedure for organ-confined pros

      6/4/25 7:45:00 AM ET
      $PROF
      Medical/Dental Instruments
      Health Care
    • Profound Medical Annual General and Special Meeting of Shareholders Voting Results

      TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 4, 2025 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders

      5/14/25 4:45:00 PM ET
      $PROF
      Medical/Dental Instruments
      Health Care
    • Profound Medical Announces First Quarter 2025 Financial Results

      TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the first quarter ended March 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).  Business Highlights Q1-2025 revenue growth of 82% over Q1-2024. Profound continued to see a wide variety of prostate disease patients treated by

      5/8/25 4:05:00 PM ET
      $PROF
      Medical/Dental Instruments
      Health Care

    $PROF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Menawat Arun Swarup bought $100,151 worth of shares (22,030 units at $4.55), increasing direct ownership by 4% to 587,089 units (SEC Form 4)

      4 - Profound Medical Corp. (0001628808) (Issuer)

      5/20/25 1:56:42 PM ET
      $PROF
      Medical/Dental Instruments
      Health Care

    $PROF
    Leadership Updates

    Live Leadership Updates

    See more
    • Profound Medical Annual General and Special Meeting of Shareholders Voting Results

      TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 4, 2025 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders

      5/14/25 4:45:00 PM ET
      $PROF
      Medical/Dental Instruments
      Health Care
    • Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

      – Mr. Tamberrino and Profound's CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final preparations for the permanent CPT® Category 1 codes for TULSA going into effect at the beginning of 2025 – TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the appointment of Tom Tamberrino as its new Chief Commercial Officer. Abbey Goodman, the Company's current CCO, will t

      10/16/24 4:15:00 PM ET
      $PROF
      Medical/Dental Instruments
      Health Care
    • Profound Medical Annual General Meeting of Shareholders Voting Results

      TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the "Meeting"). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 5, 2024 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Comp

      5/15/24 5:00:00 PM ET
      $PROF
      Medical/Dental Instruments
      Health Care

    $PROF
    Financials

    Live finance-specific insights

    See more
    • Profound Medical Announces First Quarter 2025 Financial Results

      TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the first quarter ended March 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).  Business Highlights Q1-2025 revenue growth of 82% over Q1-2024. Profound continued to see a wide variety of prostate disease patients treated by

      5/8/25 4:05:00 PM ET
      $PROF
      Medical/Dental Instruments
      Health Care
    • Profound Medical to Release First Quarter 2025 Financial Results on May 8 – Conference Call to Follow

      TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. First Quarter 2025 Results Conference Call Details: Date: Thursday, May 8, 2025 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BI2ca675b1f05

      4/17/25 8:00:00 AM ET
      $PROF
      Medical/Dental Instruments
      Health Care
    • Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results

      TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the fourth quarter and full year ended December 31, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).   Business Highlights Q4-2024 revenue growth of 108% over Q4-2023.During the fourth quarter, Profound made two key executive changes to fur

      3/6/25 4:05:00 PM ET
      $PROF
      Medical/Dental Instruments
      Health Care

    $PROF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Profound Medical Corp.

      SC 13G/A - Profound Medical Corp. (0001628808) (Subject)

      11/14/24 4:27:34 PM ET
      $PROF
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Profound Medical Corp.

      SC 13G/A - Profound Medical Corp. (0001628808) (Subject)

      8/5/24 7:50:30 AM ET
      $PROF
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Profound Medical Corp. (Amendment)

      SC 13G/A - Profound Medical Corp. (0001628808) (Subject)

      3/13/24 4:00:16 PM ET
      $PROF
      Medical/Dental Instruments
      Health Care

    $PROF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Menawat Arun Swarup bought $100,151 worth of shares (22,030 units at $4.55), increasing direct ownership by 4% to 587,089 units (SEC Form 4)

      4 - Profound Medical Corp. (0001628808) (Issuer)

      5/20/25 1:56:42 PM ET
      $PROF
      Medical/Dental Instruments
      Health Care

    $PROF
    SEC Filings

    See more
    • Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Profound Medical Corp. (0001628808) (Filer)

      6/4/25 1:30:59 PM ET
      $PROF
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Profound Medical Corp.

      8-K - Profound Medical Corp. (0001628808) (Filer)

      5/14/25 5:20:48 PM ET
      $PROF
      Medical/Dental Instruments
      Health Care
    • Profound Medical Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Profound Medical Corp. (0001628808) (Filer)

      5/8/25 4:51:04 PM ET
      $PROF
      Medical/Dental Instruments
      Health Care

    $PROF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Profound Medical with a new price target

      Lake Street initiated coverage of Profound Medical with a rating of Buy and set a new price target of $16.50

      7/23/24 8:51:59 AM ET
      $PROF
      Medical/Dental Instruments
      Health Care
    • Profound Medical upgraded by Stifel with a new price target

      Stifel upgraded Profound Medical from Hold to Buy and set a new price target of $12.00 from $9.00 previously

      7/16/24 7:45:31 AM ET
      $PROF
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on Profound Medical with a new price target

      Stifel initiated coverage of Profound Medical with a rating of Hold and set a new price target of $11.00

      11/28/23 7:53:24 AM ET
      $PROF
      Medical/Dental Instruments
      Health Care